Precision BioSciences, Inc. (DTIL)
NASDAQ: DTIL · Real-Time Price · USD
3.920
+0.070 (1.82%)
At close: Feb 19, 2026, 4:00 PM EST
3.920
0.00 (0.00%)
After-hours: Feb 19, 2026, 4:10 PM EST
Precision BioSciences Revenue
Precision BioSciences had revenue of $13.00K in the quarter ending September 30, 2025, a decrease of -97.74%. This brings the company's revenue in the last twelve months to $698.00K, down -99.07% year-over-year. In the year 2024, Precision BioSciences had annual revenue of $68.70M with 40.98% growth.
Revenue (ttm)
$698.00K
Revenue Growth
-99.07%
P/S Ratio
130.70
Revenue / Employee
$10,418
Employees
67
Market Cap
94.36M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 68.70M | 19.97M | 40.98% |
| Dec 31, 2023 | 48.73M | 23.63M | 94.15% |
| Dec 31, 2022 | 25.10M | -90.43M | -78.28% |
| Dec 31, 2021 | 115.53M | 91.24M | 375.72% |
| Dec 31, 2020 | 24.29M | 2.05M | 9.20% |
| Dec 31, 2019 | 22.24M | 11.36M | 104.34% |
| Dec 31, 2018 | 10.88M | 4.40M | 67.84% |
| Dec 31, 2017 | 6.48M | -531.00K | -7.57% |
| Dec 31, 2016 | 7.02M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionDTIL News
- 1 day ago - Precision BioSciences Announces Presentation at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference - Business Wire
- 8 days ago - Precision BioSciences Receives U.S. FDA Clearance of Investigational New Drug Application for First-in-Class PBGENE-DMD for Treatment of Duchenne Muscular Dystrophy - Business Wire
- 5 weeks ago - Precision BioSciences Sets Strategic Priorities for 2026 Focused on Continued Advancement of Clinical-Stage Programs PBGENE-HBV for Chronic Hepatitis B and PBGENE-DMD for Duchenne Muscular Dystrophy - Business Wire
- 7 weeks ago - Precision BioSciences: Potential Proof-Of-Concept Data For HBV Cure In 2026 - Seeking Alpha
- 2 months ago - Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 2 months ago - Precision Biosciences: Still Swinging And Finally Drawing Blood - Seeking Alpha
- 3 months ago - Precision BioSciences Announces Presentation of Clinical Data from the ELIMINATE-B Trial at HEP-DART 2025 - Business Wire
- 3 months ago - Precision BioSciences, Inc. (DTIL) Discusses ARCUS Platform Progress and ELIMINATE-B Clinical Trial Update for Chronic Hepatitis B Transcript - Seeking Alpha